MGMT promoter methylation in 1p19q-intact gliomas

OBJECTIVE: Standard-of-care for 1p19q-intact anaplastic gliomas is defined by the international randomized phase III CATNON trial, which found an overall survival (OS) benefit for adjuvant temozolomide (TMZ) when added to radiotherapy. Paradoxically, TMZ did not appear to benefit patients with IDH-w...

Descripción completa

Detalles Bibliográficos
Autores principales: Kinslow, Connor, Siegelin, Markus D., Iwamoto, Fabio M., Gallitto, Matthew, Neugut, Alfred I., Yu, James B., Cheng, Simon K., Wang, Tony J. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602117/
https://www.ncbi.nlm.nih.gov/pubmed/37886555
http://dx.doi.org/10.21203/rs.3.rs-3393238/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602117/
https://www.ncbi.nlm.nih.gov/pubmed/37886555
http://dx.doi.org/10.21203/rs.3.rs-3393238/v1

Ejemplares similares